DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed advanced solid tumors, including brain tumors and lymphomas, that have failed standard therapy (surgery, radiotherapy, endocrine therapy, or chemotherapy) or for which no standard therapy exists
• •* Histology requirement waived for brain stem gliomas
• •PATIENT CHARACTERISTICS:
• •Age:
• •21 and under at diagnosis
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 8 weeks
• •Hematopoietic:
• •Absolute neutrophil count at least 750/mm\^3
• •Platelet count at least 75,000/mm\^3
• •Hemoglobin at least 8.5 g/dL
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL
• •SGOT or SGPT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases)
• •Renal:
• •Creatinine no greater than 1.5 times ULN OR
• •GFR at least 70 mL/min
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •No history of severe or life-threatening hypersensitivity to camptothecin analogs
• •HIV negative
• •No other concurrent severe or uncontrolled medical illness
• •No systemic infection
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Recovered from prior immunotherapy
• •Chemotherapy:
• •See Disease Characteristics
• •Recovered from prior chemotherapy
• •Endocrine therapy:
• •See Disease Characteristics
• •Radiotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior extensive radiotherapy involving cranial, whole pelvic, or at least 25% of bone marrow reserve
• •Recovered from prior radiotherapy
• •Concurrent localized radiotherapy for pain allowed
• •Surgery:
• •See Disease Characteristics
• •Recovered from prior surgery
• •Other:
• •No other concurrent antitumor therapy
• •No concurrent drugs that induce or inhibit CYP3A enzyme